ARGX
argenx SE$882.41
LiveJun 08, 2026
Market cap
$54.61B
52w range
510.06 – 934.62
P / E
—
EPS
—
Volume
484.38K
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on argenx SE’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $1,052.00 (+19.22%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00% | +10.42% | +12.82% | +22.93% | -2.04% | +4.93% | +51.20% | +125.52% | +229.52% | +3736.57% | +3736.57% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$882.41
352 sh
Bid
$863.05
1 sh
Ask
$900.00
1 sh
Spread
$36.950
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Technology+2.24%
- Real Estate+0.71%
- Communication Services+0.40%
- Financial Services+0.18%
- Consumer Cyclical+0.00%
- Healthcare-0.50%
- Industrials-0.91%
- Energy-1.52%
- Utilities-1.53%
- Consumer Defensive-1.61%
- Basic Materials-2.64%
Top industries (issuer's industry highlighted)
- Biotechnology+1.68%
- Silver-8.27%
- Copper-7.22%
- Gold-5.40%
- Oil & Gas Energy-4.69%
- Medical - Healthcare Information Services-4.41%
- Oil & Gas Drilling-3.75%
- Financial - Capital Markets+3.44%
- Beverages - Non-Alcoholic-3.42%
- Insurance - Reinsurance+3.32%
- Semiconductors+3.32%
- REIT - Healthcare Facilities-3.27%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?zacks.com·Jun 08, 2026
- argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conferencemarketbeat.com·Jun 05, 2026
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026globenewswire.com·Jun 03, 2026
- argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMGglobenewswire.com·May 08, 2026
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMGglobenewswire.com·May 08, 2026
- argenx to Present at BofA Securities 2026 Health Care Conferenceglobenewswire.com·May 06, 2026
Recent analyst activity
DB- Jun 04, 2026GradeBuy → BuyH.C. Wainwright Reiterates Buy Rating on argenx SE (ARGX)H.C. Wainwright
- Jun 04, 2026PT$940.00H.C. Wainwright Reiterates Buy Rating on argenx SE (ARGX)H.C. Wainwright
- Jun 01, 2026GradeOverweight → OverweightArgenx price target raised to $1,291 from $1,260 at Wells FargoWells Fargo
- Jun 01, 2026PT$1291.00Argenx price target raised to $1,291 from $1,260 at Wells FargoWells Fargo
Peers
No peer list available for ARGX.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|